Table 4.
Summary of clinical studies involving the use of isolated hADSCs on spine disorders for the last 10 years.
| Target Disorder | No. of Patients Treated (Age: Mean ± SD) |
ADSC Type | ADSC Delivery |
Study Outcome |
Year | Ref. No. | |
|---|---|---|---|---|---|---|---|
| 1 | Degenerative spondylolisthesis (TLIF) 1 | 3 (48.70 ± 14.30) | Autologous, derived from abdominal fat | ADSC seeded DBM 2 was implanted into the disc space | Grad 3 fusion, VAS and ODI 3 improved | 2017 | [196] |
| 2 | Chronic discogenic low back pain | 10 (43.50 ± 10.16) | Autologous, derived from abdominal fat | Percutaneous injection of ADSC in combination with HA 4 derivatives | Safe and tolerable without no adverse events. | 2017 | [197] |
1 Transforaminal lumbar interbody fusion (TLIF), 2 demineralized bone matrix (DBM), 3 Oswestry disability index (ODI), 4 hyaruronic acid (HA).